Loading
Momelotinib is the JAK inhibitor designed for anaemic myelofibrosis patients: it can improve haemoglobin while shrinking the spleen.
Momelotinib inhibits JAK1 and JAK2 to shrink the spleen and relieve symptoms, and additionally blocks ACVR1 (ALK2), which lowers hepcidin and frees iron for red-cell production. That second action is why it was developed for myelofibrosis patients whose anaemia rules out or limits other JAK inhibitors. MOMENTUM (2023) compared it with danazol in symptomatic anaemic patients after a prior JAK inhibitor: symptom response was superior, transfusion independence non-inferior, and spleen response better. The earlier SIMPLIFY-1 and SIMPLIFY-2 trials against ruxolitinib and best available therapy built the anaemia signal. It was approved in the US in 2023 and the EU in 2024 for myelofibrosis with anaemia. For a newcomer, momelotinib is the JAK inhibitor chosen when low haemoglobin is the dominant problem.
Inhibits JAK1/2 for spleen and symptoms and ACVR1 (ALK2) to lower hepcidin and improve anaemia. Connects to JAK2, JAK1 and ACVR1 (ALK2).
1.Momelotinib slips into a pocket on JAK2.
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026).
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy. Myelofibrosis with anaemia documented.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE TA957. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2023 | Intermediate/high-risk myelofibrosis with anaemia |
| EU | 2024 | Myelofibrosis with moderate-to-severe anaemia |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
MOMENTUM addressed the biggest gap left by ruxolitinib: patients whose anaemia makes standard JAK inhibition hard to give. Momelotinib is now the preferred option for anaemic, previously treated myelofibrosis and is being adopted in first line for anaemic patients. The absolute symptom benefit is modest and durable disease modification has not been shown.
COMFORT-I turned the 2005 discovery of the JAK2 V617F mutation into the first effective medicine for myelofibrosis, transforming symptom control for a disease with no prior standard. Ruxolitinib is still the reference first-line therapy, with fedratinib, pacritinib and momelotinib as alternatives for cytopenic patients. It does not eliminate the malignant clone or reverse fibrosis in most patients.
Query for this drug: (TITLE:"Momelotinib" OR ABSTRACT:"Momelotinib" OR TITLE:"Ojjaara" OR ABSTRACT:"Ojjaara" OR TITLE:"Omjjara" OR ABSTRACT:"Omjjara") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Momelotinib, not a curated reading list.
Shares ACVR1 (ALK2), DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores), MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, JAK1.
Shares DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores), COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, JAK2, Primary myelofibrosis.
Shares MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.
Shares MOMENTUM, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.
Shares Polycythaemia vera (PV), JAK2, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores), Polycythaemia vera (PV), JAK2, Primary myelofibrosis.
Shares Post-PV myelofibrosis (spent phase), DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores), MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, JAK1.